The Princess of Asturias Foundation

Sección de idiomas

Languages

Fin de la sección de idiomas

Sección de utilidades

Contact

Careers

Fin de la sección de utilidades

Síguenos en:

Start of Main Menu

End of Main Menu

#PrincessofAsturiasAwards

Start of Secondary Menu

End of Secondary Menu

You are in:

Laureates

Start of main content

Gregory Winter and Richard A. Lerner

Prince of Asturias Award for Technical & Scientific Research 2012

The researchers Gregory Winter and Richard A. Lerner stand at the forefront of research on the immune system. The advances in the use of antibodies as therapeutic tools have provided new ways of preventing and treating immune disorders, degenerative diseases and different types of tumours. In many cases, the use of antibodies has alleviated the suffering of patients and has halted the progression of the disease. These researchers have managed to create a synthetic immune system in the test tube, as well as demonstrating its preventive and therapeutic potential due to exceeding the natural antibody repertoire the human body can generate.

Sir Gregory Winter

Sir Gregory Winter (UInited Kingdom, 1951) studied Natural Sciences at Trinity College, Cambridge and undertook his PhD studies at the Laboratory of Molecular Biology (LMB) at the Medical Research Council (MRC), an institution of which he has been deputy director. He is Master of Trinity College.

Within the LMB, Winter has been one of the leading biochemists in innovative techniques for creating monoclonal therapeutic antibodies and one of the pioneers in the development of techniques for the humanization of these antibodies, a key step for the human immune system not to identify them as foreign agents. He holds numerous patents and, in addition to being scientific advisor to several genetic engineering firms, was the founder in 1989 of Cambridge Antibody Technology, a biotechnology company promoted by the LMB to market these antibodies, including adalimumab for treating rheumatoid arthritis and Crohn’s disease. He also founded the companies Domantis in 2000 and Bicycle Therapeutics in 2009.

Commander of the British Empire and a Fellow of The Royal Society, the Academy of Medical Sciences of the United Kingdom, the Australian Academy of Technological Sciences and Engineering and the Swedish Academy of Engineering Science, Winter has received the Louis Jeantet Prize for Medicine (Switzerland, 1989), the Emil von Behring Prize (Germany, 1990), the Milan Award (Italy, 1990), the Scheele Award of the Swedish Academy of Pharmaceutical Sciences (1994), the King Faisal International Prize in Medicine (Saudi Arabia, 1995), the Biochemical Society Award (UK, 2006) and the BioIndustry Association Award (UK, 2008), among other distinctions.

Richard Alan Lerner

Richard Alan Lerner (Chicago, United States, 1938 - San Diego, United States, 2021) studied medicine at Northwestern University and Stanford, earning his PhD at the latter in 1964. Following internship at the Palo Alto Stanford Hospital in 1965, he began his career in research and teaching in the Department of Experimental Pathology at the Scripps Research Institute in La Jolla (California), an institution of which he was president from 1991 to 2012. He was the Lita Annenberg Hazen Professor of Immunochemistry in the Department of Molecular Biology at Scripps and a member of the Skaggs Institute for Chemical Biology.

Lerner was the architect of the most important advance since the discovery of monoclonal antibodies a quarter century ago: the conception, design and creation of combinatorial antibody libraries, the most widely used of all libraries in the field of biochemistry and which enabled a broadening of the scope of action of the immune system. Lerner set the stage in an article published in Science in 1989 and all the advances produced in the change in combinatorial libraries derived directly or indirectly from this article. Furthermore, in 1991, Lerner identified the essence of the production of antibodies without immunization and his method has remained the most efficient way to produce fully human antibodies. Moreover, Lerner has been a pioneer in the development of what are known as catalytic antibodies, a strategy to accelerate and catalyse chemical reactions for which traditional methods are not efficient.

Author of more than four hundred scientific papers, Lerner held honorary degrees from seven universities in Europe and America. Among other awards, he has received the Wolf Prize in Chemistry (Israel, 1995), the William B. Coley Award from the Cancer Research Institute (USA, 1999) and the Paul Ehrlich and Ludwig Darmstaedter Prize (Germany, 2003).

End of main content

Sección de utilidades

Fin de la sección de utilidades

PDF Accesible

Start of content